Editorial

Helicobacter pylori Eradication in Diabetic Patients: Still Far Off the Treatment Targets

Authors: Christian Selinger, MD, MRCP, Andrew Robinson, PhD, FRCP

Abstract

Over 25 years after Barry and Marshall first linked it with peptic ulcer disease, Helicobacter pylori (HP) remains one of the most common infections worldwide.1,2 HP is associated with gastrointestinal problems ranging from simple non-ulcer dyspepsia to uncomplicated or complicated (perforation or bleeding) peptic ulcer disease, mucosa-associated lymphatic tissue (MALT) lymphoma disease, and gastric adenocarcinomas.3Extraintestinal manifestations of HP include iron deficiency anemia and idiopathic thrombocytopenic purpura. Detection of HP can be achieved endoscopically by rapid urease testing, histology, or culture.4 Non-endoscopic methods include serological antibody testing, 14C-labeled urea breath test (UBT), and fecal antigen testing.4

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–1315.
 
2. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997;10:720–741.
 
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management ofHelicobacter pylori infection: the Maastricht III Consensus report. Gut 2007;56:772–781.
 
4. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management ofHelicobacter pylori infection. Am J Gastroenterol 2007;102:1808–1825.
 
5. Lee JM, Breslin NP, Fallon C, et al. Rapid urease tests lack sensitivity in Helicobacter pyloridiagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 2000;95:1166–1170.
 
6. Demir M, Gokturk HS, Ozturk NA, et al. Clarithromycin resistance and efficacy of clarithromycin-containing triple eradication therapy for Helicobacter pylori infection in type 2 diabetes mellitus patients. South Med J 2009;102:1116–1120.
 
7. Gasbarrini A, Ojetti V, Pitocco D, et al. Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1999;11:713–716.
 
8. Gasbarrini A, Ojetti V, Pitocco D, et al. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand J Gastroenterol 2000;35:260–263.
 
9. Sargýn M, Uygur-Bayramicli O, Sargýn H, et al. Type 2 diabetes mellitus affects eradication rate ofHelicobacter pylori. World J Gastroenterol 2003;9:1126–1128.
 
10. Demir M, Gokturk HS, Ozturk NA, et al. Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. Am J Med Sci2009;338:459–464.
 
11. Ataseven H, Demir M, Ramazan G. Effect of sequential treatment as a first-line therapy forHelicobacter pylori eradication in patients with diabetes mellitus. South Med J 103;10:988–992.
 
12. Tong JL, Ran ZH, Shen J, et al. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009;34:41–53.